Discover trends, market shifts, and competitive outlooks for the primary biliary cholangitis industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Has the Primary Biliary Cholangitis Market Growth Performance Trended Historically, And What Lies Ahead?

The market size for primary biliary cholangitis has seen swift expansion in the past few years. The projection is that it will escalate from $0.98 billion in 2024 to $1.09 billion in 2025, recording a compound annual growth rate (CAGR) of 11.8%. Factors contributing to this growth during the historic period include enhanced understanding of the disease, a surge in global healthcare spending, strategic partnerships in the healthcare domain, emphasis on patient advocacy, and government endeavors aimed at improving liver health.

The market size for primary biliary cholangitis is forecasted to experience substantial growth in the coming years, reaching $1.6 billion by 2029 with a compound annual growth rate (CAGR) of 9.9%. The surge in the predicted period is affiliated with the growth of biomarker studies, global initiatives in managing rare diseases, enhanced cooperation in clinical trials, and a patient-focused healthcare system, as well as a rising demand for liver transplants. Key forthcoming trends encompass advancements in biomarker exploration, an increasing stress on non-invasive diagnostic methods, the intensified focus on immunomodulatory therapies, the incorporation of artificial intelligence (AI), patient-reported repercussions during clinical trials, the use of telemedicine for patient administration, emphasis on combination treatments, and the advent of therapies targeting fibrosis.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13520&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Primary Biliary Cholangitis Market?

The escalating incidences of smoking are anticipated to stimulate the expansion of the primary biliary cholangitis market in the forthcoming period. Smoking, which is the process of inhaling and exhaling smoke from burning tobacco or other substances, is identified as a risk factor for liver diseases like PBC. It is predicted that amplified rates of smoking will result in a greater number of people seeking medical help for liver-associated problems. For example, as per Statistics Canada, a government agency of Canada, the production of cigarettes saw a 2.2% hike in July 2023 compared to June 2023. In addition, cigarette sales witnessed a 2.6% rise in June, hitting 1.4 billion units, more than what it was in May. Consequently, the growth in smoking habits will fuel the primary biliary cholangitis market’s growth.

Growth in Primary Biliary Cholangitis Market Driven by Spurt in Liver Cancer Cases

Which Key Market Segments Comprise the Primary Biliary Cholangitis Market and Drive Its Revenue Growth?

The primary biliary cholangitis market covered in this report is segmented –

1) By Treatment Type: Drugs, Liver Transplantation

2) By Diagnosis: Imaging Tests, Magnetic Resonance Elastography (MRE), Magnetic Resonance Cholangiopancreatography (MRCP), Ultrasound, Fibroscan, Blood Tests, Cholesterol Test, Antibody Tests, Liver Tests, Other Diagnoses

3) By End-Users: Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Drugs: Ursodeoxycholic Acid (UDCA), Obeticholic Acid (OCA), Fibrates, Immunosuppressive Drugs, Other Targeted Therapies

2) By Liver Transplantation: Orthotopic Liver Transplantation (OLT), Living Donor Liver Transplantation, Hepatobiliary Surgery For Liver Transplant

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=13520&type=smp

Which Areas Are Leading Regions in the Primary Biliary Cholangitis Market Expansion Across the Globe?

North America was the largest region in the primary biliary cholangitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Market Trends in thePrimary Biliary Cholangitis Market Over the Coming Years?

Firms in the primary biliary cholangitis market are investing in the development of unique and specialized therapies, such as orphan drugs that combine obeticholic acid (OCA) and bezafibrates aimed at treating primary biliary cholangitis (PBC), to secure exclusive control of the market. The use of a drug designated as an orphan that combines OCA and bezafibrate serves as a more thorough and efficient method for managing PBC treatment, with the potential to enhance the quality of life for those suffering from this uncommon disease. For instance, in May 2023, Intercept Pharmaceuticals, Inc., a biopharmaceutical firm based in the United States, was granted orphan drug designation by the FDA for the combination of obeticholic acid (OCA) and bezafibrate, a PPAR agonist, as a possible treatment for primary biliary cholangitis (PBC), a deteriorative liver disease, and obeticholic acid (sold as Ocaliva) has been approved for PBC in the United States.

View the full report here:

https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report

How Is the Primary Biliary Cholangitis Market Conceptually Defined?

Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by the progressive inflammation and destruction of the small bile ducts within the liver. This condition can lead to impaired bile flow, liver damage, and various related complications. PBC primarily affects middle-aged women and is often associated with symptoms such as fatigue, itching, and abdominal discomfort.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13520

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model